Related Experiment Videos
Statin therapy for stroke prevention
Abdullah Nassief1, James D Marsh
1Washington University School of Medicine, Saint Louis, MO, USA.
Insights
Statins effectively reduce stroke risk in patients with and without coronary artery disease (CAD). This review of recent trials confirms statins
Area of Science:
- Cardiovascular Medicine
- Neurology
- Pharmacology
Background:
- Statins are primarily prescribed for cardiovascular risk reduction in patients with coronary artery disease (CAD).
- Evidence for statin use in stroke risk reduction, particularly in patients without CAD, requires updated review.
Purpose of the Study:
- To review recent clinical trials for new evidence on statin therapy's efficacy in reducing stroke risk.
- To evaluate statin benefits across diverse patient populations, including those with and without CAD.
Main Methods:
- Systematic review of recent clinical trials investigating statin use and stroke risk.
- Analysis of data from trials such as TNT and SPARCL.
Main Results:
- Statin therapy significantly reduces stroke risk in patients with CAD, with no increased risk of hemorrhagic stroke.
- Evidence supports statin use for stroke risk reduction in patients without CAD who have high cardiovascular risk or diabetes mellitus.
- Intensive statin therapy post-cerebrovascular event (SPARCL trial) reduced stroke risk and severity.
Conclusions:
- Statins offer significant stroke risk reduction benefits beyond their established cardiovascular advantages.
- Physicians should consider statin therapy for all individuals identified as high risk for stroke.
Background And Purpose:
Statins are widely used to reduce the risk of stroke in patients with coronary artery disease (CAD), but less so in patients without CAD. We reviewed recent trials for new evidence for the reduction in risk of stroke.
Summary Of Review:
In patients with CAD, moderate-intensity statin treatment has been associated with reductions in risk of stroke, with no increase in hemorrhagic stroke. Additionally, in the TNT trial, intensive lipid lowering provided further stroke risk reduction compared with moderate lipid lowering in patients with stable CAD. Evidence is now available that statin therapy also reduces stroke risk in patients without CAD but at high cardiovascular risk, or with diabetes mellitus. The SPARCL trial showed that intensive statin therapy started within 6 months after a cerebrovascular event significantly reduced stroke risk and stroke severity. Low cholesterol levels have been associated with increased risk of hemorrhagic stroke, but although an increased risk of hemorrhagic stroke was observed in patients with prior hemorrhagic stroke in SPARCL, this was not related to low-density lipoprotein cholesterol levels. Clinical trials have recruited few patients with both coronary and cerebrovascular disease, but these patients are also expected to experience significant cardiovascular benefit with statin therapy.
Conclusions:
Trial data show that statins reduce the risk of stroke, in addition to providing cardiovascular benefits. Consequently, physicians should consider statin therapy in all patients at high risk of stroke.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Atherosclerosis III: Management
Coronary Artery Disease V: Interprofessional Care
Atherosclerosis IV: Nursing Management
Ischemic Stroke l: Introduction
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...